Used in cancer immunotherapy to block the CD47 protein on tumor cells, which helps cancer evade the immune system. By inhibiting CD47, the antibody enables macrophages and other immune cells to recognize and destroy cancer cells. Investigated in clinical trials for hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and non-Hodgkin lymphoma, as well as solid tumors. Often combined with other antibodies like rituximab or azacitidine to enhance anti-tumor activity. Shows potential in promoting phagocytosis and activating adaptive immune responses against cancer.